Drugs / GSK1278863A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02348372 | Mar → Jun 2011 | anemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01319006 | Feb → Apr 2011 | anemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00935831 | Aug 2009 → Apr 2010 | kidney disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00750256 | Jul → Dec 2008 | anemia | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1278863A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00935831 ↗ |
| Known as | 1278863A | “Compound 1278863A is a novel small molecule agent, which stimulates erythropoiesis through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs).” NCT00935831 ↗ |
| Action | Inhibit | “through inhibition of hypoxia-inducible factor (HIF)-prolyl hydroxylases (EGLNs)” NCT00935831 ↗ |
| Modality | Small molecule | “Compound 1278863A is a novel small molecule agent” NCT00935831 ↗ |
| Route | Oral | “Single Oral Doses of GSK1278863A in Healthy Subjects” NCT00750256 ↗ |